Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C21H30N2O.2ClH |
| Molecular Weight | 399.398 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.CC(C)(C)C1=NC2=C(C=CC=C2)C(=C1)C(O)CCC3CCNCC3
InChI
InChIKey=JBFXAZXAVFRMKF-UHFFFAOYSA-N
InChI=1S/C21H30N2O.2ClH/c1-21(2,3)20-14-17(16-6-4-5-7-18(16)23-20)19(24)9-8-15-10-12-22-13-11-15;;/h4-7,14-15,19,22,24H,8-13H2,1-3H3;2*1H
Quinacainol (also known as PK 10139 or RP 54272) is a quinolinemethanol derivative patented by Pharmindustrie as an antiarrhythmic agent. Quinacainol acts as a sodium channel antagonist and demonstrated both class Ia and Ic antiarrhythmic properties. Quinacainol blocked sodium currents in a concentration-dependent manner and with a potency similar to that of quinidine. Quinacainol produces a slowing of action potential conduction, consistent with a block of sodium channels, and a slight prolongation of action potential duration, consistent with a block of potassium currents.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
83255-74-7
Created by
admin on Sat Dec 16 20:12:52 GMT 2023 , Edited by admin on Sat Dec 16 20:12:52 GMT 2023
|
PRIMARY | |||
|
DTXSID601003223
Created by
admin on Sat Dec 16 20:12:52 GMT 2023 , Edited by admin on Sat Dec 16 20:12:52 GMT 2023
|
PRIMARY | |||
|
3068237
Created by
admin on Sat Dec 16 20:12:52 GMT 2023 , Edited by admin on Sat Dec 16 20:12:52 GMT 2023
|
PRIMARY | |||
|
JAH39J59YH
Created by
admin on Sat Dec 16 20:12:52 GMT 2023 , Edited by admin on Sat Dec 16 20:12:52 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
